

Multiple Sclerosis Journal

<http://msj.sagepub.com/>

Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

DW Langdon, MP Amato, J Boringa, B Brochet, F Foley, S Fredrikson, P Hämäläinen, H-P Hartung, L Krupp, IK Penner,
AT Reder and RHB Benedict

Mult Scler published online 21 December 2011

DOI: 10.1177/1352458511431076

The online version of this article can be found at:

<http://msj.sagepub.com/content/early/2011/12/21/1352458511431076.1>

Published by:



<http://www.sagepublications.com>

Additional services and information for *Multiple Sclerosis Journal* can be found at:

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Open
Access**

Email Alerts: <http://msj.sagepub.com/cgi/alerts>

Subscriptions: <http://msj.sagepub.com/subscriptions>

Reprints: <http://www.sagepub.com/journalsReprints.nav>

Permissions: <http://www.sagepub.com/journalsPermissions.nav>

>> [OnlineFirst Version of Record](#) - Dec 21, 2011

[OnlineFirst Version of Record](#) - Dec 21, 2011

[What is This?](#)

Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

Multiple Sclerosis Journal
0(0) 1–8
© The Author(s) 2012
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/1352458511431076
msj.sagepub.com


DW Langdon¹, MP Amato², J Boringa³, B Brochet⁴, F Foley⁵,
S Fredrikson⁶, P Hämmäläinen⁷, H-P Hartung⁸, L Krupp⁹,
IK Penner¹⁰, AT Reder¹¹ and RHB Benedict¹²

Abstract

Background: Cognitive impairment in MS impacts negatively on many patients at all disease stages and in all subtypes. Full clinical cognitive assessment is expensive, requiring expert staff and special equipment. Test versions and normative data are not available for all languages and cultures.

Objective: To recommend a brief cognitive assessment for multiple sclerosis (MS) that is optimized for small centers, with one or few staff members, who may not have neuropsychological training and constructed to maximize international use.

Methods: An expert committee of twelve members representing the main cultural groups that have so far contributed considerable data about MS cognitive dysfunction was convened. Following exhaustive literature review, peer-reviewed articles were selected to cover a broad spectrum of cultures and scales that targeted cognitive domains vulnerable to MS. Each was rated by two committee members and candidate scales were rated on psychometric qualities (reliability, validity, and sensitivity), international application, ease of administration, feasibility in the specified context, and acceptability to patients.

Results: The committee recommended the Symbol Digit Modalities Test, if only 5 minutes was available, with the addition of the California Verbal Learning Test – Second Edition and the Brief Visuospatial Memory Test – Revised learning trials if a further 10 minutes could be allocated for testing.

Conclusions: A brief cognitive assessment for MS has been recommended. A validation protocol has been prepared for language groups and validation studies have commenced.

Keywords

multiple sclerosis, cognition information processing, memory, assessment, psychometrics, neuropsychology, SDMT, CVLT-II, BVM-T-R

Date received 16th October 2011; accepted: 3rd November 2011

Introduction and rationale

Cognitive impairment in multiple sclerosis reduces patients' life satisfaction and health-related quality of life. It is probably the most important determinant of employment status and associated societal costs, and also adversely affects driving safety, household task completion, social activity, physical independence, rehabilitation progress, coping, treatment adherence and mental health.¹ There is a high functional impact on young adults in demanding environments. Reported cognitive impairment prevalence rates are between 43% and 70%. They occur in all disease stages, including clinically isolated syndrome (CIS) and early relapsing–remitting MS (RRMS). Cognition is only loosely related to disease duration² and physical disability (in some instances clearly dissociated)³ and is more strongly related to brain MRI parameters, especially atrophy.⁴

¹Royal Holloway, University of London, Surrey, UK.

²Careggi University Hospital, Florence, Italy.

³Meander Medisch Centrum, Amersfoort, The Netherlands.

⁴Universite de Bordeaux, France.

⁵Yeshiva University, Bronx, NY, USA and Holy Name Hospital Multiple Sclerosis Center, Teaneck, NJ, USA.

⁶Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden.

⁷Masku Neurological Rehabilitation Centre, Masku, Finland.

⁸Heinrich-Heine-Universität, Duesseldorf, Germany.

⁹Albert Einstein College of Medicine New York, USA.

¹⁰University of Basel, Switzerland.

¹¹University of Chicago, USA.

¹²Jacobs Neurological Institute, New York, USA.

Corresponding author:

Professor DW Langdon, Royal Holloway, University of London, Egham, Surrey, TW20 0EX, UK.

Email: d.langdon@rhul.ac.uk

Cognitive deficits typically involve a few cognitive domains, spare language and are often undetected at consultation.⁵ Information processing speed is the most vulnerable cognitive ability, followed by episodic memory, and executive function.⁶ Deficits may be mild. There is high interpatient variability, in part due to varying compensation capacities (cognitive reserve).⁷ Patients may not be fully aware of their deficits, or may not report them reliably: depression results in over-reporting,⁸ whilst metamemory impairment and insight loss lead to underestimation in up to a third.⁹ MS cognitive deficits occur in the context of sensory and motor impairments¹⁰ and reduced functioning and engagement is easily attributable to physical disabilities. Cognitive impairment is not always at the forefront of the neurologist's mind, although cognitive decline could be as important to the patient as physical relapses or MRI lesions.¹¹

Addressing cognitive dysfunction is recognised as a quality indicator in MS care.¹² However, psychometric assessment of cognitive status requires time-consuming expert evaluation with specialist materials. The most commonly utilised batteries of neuropsychological tests validated in MS are the 45-min Brief Repeatable Battery of Neuropsychological tests (BRB-N)¹³ and the 90-min Minimal Assessment of Cognitive Function in MS (MACFIMS).¹⁰ Comprehensive clinical cognitive assessment requires additional expertise in test selection, administration and interpretation. This is not routinely available outside specialist centres.¹⁰ Non-specialist cognitive evaluation tools are unsatisfactory. The Expanded Disability Status Scale offers only a rudimentary estimate of cognitive function.¹⁴ Widely used screening instruments, such as the Mini Mental State Examination, are insensitive to the MS cognitive footprint.¹⁵ All of the above considerations point to a clear need for a short, well-validated and widely accepted tool, which captures the cognitive performance of MS patients, and can be used in everyday practice by clinical neurologists or administered by local healthcare workers.¹⁶

Objective

Our objective was to recommend a clinical tool for neurologists and healthcare professionals working with people with MS, which was not designed to be either a cognitive screen or full assessment, but rather a brief monitoring instrument. It would be optimised for centres where neuropsychologists are not available. Identifying a brief measurement tool with adequate reliability, validity, sensitivity and specificity would allow for more widespread, accurate cognitive evaluations. A validated record of cognitive disability incorporated into routine clinical practise would be beneficial. Baseline ratings and regular follow-up assessments would optimise patient management. Data from this cognitive monitoring tool could assist therapeutic decision

making, including determining how best to support patients' involvement in disease management. Information and counselling could be offered, facilitating adjustment at work and home. The effect of a start or shift in Disease Modifying Drug (DMD) treatment on cognition could be monitored, and also the use of cognition enhancers (provided that sufficient evidence of efficacy is achieved).¹⁷ The brief cognitive tool could also be integrated into more detailed, specialist cognitive assessments and used to indicate which patients require expert evaluation, targeting this resource more efficiently and equitably. From a global perspective, there are currently no cognitive measures for MS that are internationally validated and standardised, which is a challenge for international study design.

Methods

A committee of seven neurologists and five neuropsychologists was convened, selected for their expertise in research and clinical aspects of MS cognition, and to represent the language groups who had so far contributed most significantly to the MS cognition literature. There were two co-chairs (one European, one American). A list of 80 scientific articles from peer review journals (<http://msj.sagepub.com/content/early/recent>) was assembled after a MEDLINE search in June 2010 by the co-chairs (D.L. and R.B.). These were chosen to represent a broad international spectrum of cognitive scales and their psychometric properties, including recent key review articles to allow the committee to identify any omissions. The full list was circulated to the committee and members were invited to suggest amendments and additions. Prior to the consensus meeting, a subset of articles was circulated to each committee member with standardised rating scales for completion. No member reviewed an article on which they were an author. Each article was rated independently by two committee members on three psychometric standards (reliability, validity and sensitivity) and four pragmatic standards (international applicability, ease of administration, feasibility in the specified context and acceptability to patients). All ratings were 3–1 (3 = excellent, 2 = satisfactory, 1 = unsatisfactory). The mean rating for each scale and each standard were calculated, and then the mean overall rating (MOR) for psychometric and pragmatic qualities separately. Raters were also invited to submit qualitative comments and judgements. Ratings and comments were collated for each candidate measure, and all collated ratings, from individual to mean scores, were presented to the committee and fully discussed.

Consensus criteria

To meet the specified objectives of the cognitive monitoring tool, it was decided that the recommended battery should be completed in 15 min and not require any special equipment (beyond papers, pen and stop watch) or specific

assessor training. The battery should be easily performed in a clinical setting. Discussions at the consensus meeting led to agreement that the domains of information processing speed, verbal memory and visual memory could be included. Executive function scales were felt to be too long and too challenging to administer in the target context. It was acknowledged that a wide variety of cognitive presentations can be seen clinically,¹⁸ but it was felt that a battery of scales addressing the three domains identified would capture a reasonable proportion of significant cognitive impairment in large clinical samples.

Recommended monitoring tests

Information processing speed. There are two widely used tests of attention and processing speed in multiple sclerosis: the Paced Auditory Serial Addition Task (PASAT)¹³ and the Symbol Digit Modalities Test (SDMT, oral form).¹⁹ Both are included in the BRB-N and the MACFIMS. The SDMT achieved higher ratings, with a psychometric MOR of 2.8 and a pragmatic MOR of 3.0. In comparison, the PASAT achieved a psychometric MOR of 2.6 and a pragmatic MOR of 1.9. Discussion acknowledged that the SDMT is more congenial for both patient and assessor, takes less time to complete, requires less expertise and experience of the assessor and unlike the PASAT, does not require special equipment for auditory presentation of stimuli. It has equal psychometric validity to the PASAT.²⁰ The committee considered the evidence that the PASAT has detected therapeutic efficacy of disease modifying medication on cognition,^{21,22} but felt that the SDMT was the better choice for the specified context on feasibility grounds.

The SDMT¹⁹ was recommended as the test of information processing speed. The test consists of single digits paired with abstract symbols (Figure 1). Rows of the nine symbols are arranged pseudo-randomly. The patient must say the number that corresponds with each symbol. The SDMT can be completed within 5 min, including instructions, practice and testing. The good psychometric properties of the SDMT are well described.²³ The SDMT has a reported sensitivity of 82% and a specificity of 60%.²⁴ It has validations in several countries.^{2,24-26} Estimates of practice effects and change indices are available.²⁷ The SDMT has a high sensitivity to cognitive impairment in MS.^{6,26,28} It has been shown to be the best predictor of MS cognitive impairment in both the BRB-N and MACFIMS.⁶ The SDMT is reliable when administered by nursing staff over several months, with minimal practice effects (0.2).²⁹ There is also evidence for the sensitivity of the SDMT to cognitive change in MS.^{2,25,30} The SDMT is well validated against both conventional brain MRI parameters (including atrophy,³¹ brain parenchymal fraction (BPF) and third ventricular width,³² atrophy at baseline predicting SDMT change;³³ cortical lesion number and white matter lesion volume,³⁴ cortical lesion volume,^{32,34,35} cortical lesion



Figure 1. Example of stimuli of the SDMT type.

volume change correlating with SDMT change,³⁶ correlation with some deep grey matter (DGM) nuclei,³⁷ including thalamic fraction;³² and fMRI (fractional anisotropy).³⁸ The SDMT has also been shown to have external clinical validity, being significantly linked to both current³⁹ and future³⁰ employment status.

Verbal memory (immediate recall). Again two candidate scales emerged: The California Verbal Learning Test-II (CVLT-II)⁴⁰ and the Selective Reminding Test (SRT).¹³ The CVLT-II is in the MACFIMS and the SRT is in the BRB-N. The CVLT-II achieved a psychometric MOR of 2.9 and a pragmatic MOR of 2.6. In contrast, the SRT achieved a psychometric MOR of 2.5 and a pragmatic MOR of 2.2. It was noted that the SRT format required more expertise in administration and scoring, compared to the simple list recall format of the CVLT-II. The committee decided that the first five recall trials of the CVLT-II (CVLT-II T1-5) had sufficient psychometric rigour, in particular sensitivity to MS impairment,^{41,42} to be suitable for inclusion in BICAMS. CVLT-II T1-5 has been previously recommended as part of a brief MS cognitive assessment.⁴³ The first five recall trials have a high degree of interdependence to other sections of the CVLT-II.⁴² Although this renders conclusions from the validity data

Apple
Bear
Piano
Hammer
Banana
Chisel
Trumpet
Orange
Lion
Wrench
Peach
Saw
Drum
Tiger
Violin
Giraffe




Figure 2. Example stimuli of the CVLT-II type.

based on the full CVLT-II inferential, it also reduces the range of cognitive processes involved.⁴¹ The recommendation carries the pragmatic advantage of reduced administration time (and possible patient fatigue effects), and a lesser requirement for assessor expertise and experience compared to the full CVLT-II, which suit our target context.

The recommended verbal memory scale is the CVLT-II T1-5.⁴⁰ This comprises a 16-item word list, with four items belonging to each of four categories, arranged randomly (Figure 2). The list is read aloud five times in the same order to the patient, at a slightly slower rate than one item per second. Patients are required to recall as many items as possible, in any order, after each reading of the list. The CVLT-II T1-5 can be completed in 5–10 min, including instructions, testing and responses. The CVLT-II T1-5 has been validated with brain MR total lesion area and right superior frontal atrophy,⁴⁴ MR T1 and FLAIR lesion volume, BPF and third ventricular width³² and MR diffusion measures.⁴² The full CVLT-II has been validated against brain MRI parameters (cortical lesion number;³⁴ correlation with some DGM nuclei volume,³⁷ including thalamic fraction).³² The full CVLT-II also has external clinical validity, in differentiating employed MS patients from patients not employed due to MS.⁴¹

Visual Memory (immediate recall). Once again, two major candidate scales emerged: the Brief Visuospatial Memory

Figure 3. Example test stimuli of the BVMT-R type.

Test Revised (BVMT-R)⁴⁵ and the 10/36 Spatial Recall Test.¹³ The BVMT-R is in the MACFIMS and the 10/36 is in the BRB-N. The BVMT-R achieved a psychometric MOR of 3.0 and a pragmatic MOR of 2.2. In comparison, the 10/36 achieved a psychometric MOR of 2.3 and a pragmatic MOR of 2.6. The committee's discussion highlighted the reliability of the BVMT-R, the special equipment needed for the 10/36 and the possible ceiling effect on the 10/36.^{7,28} As in the deliberations about the verbal memory scale, the conclusion was reached that the first three recall trials of the BVMT-R (BVMTR T1-3) would be the scale recommended for BICAMS, with similar advantages and caveats to those stated above in connection with the CVLT-II T1-5.

The BVMT-R T1-3⁴⁵ is recommended. The BVMT-R T1-3 requires the patient to inspect a 2×3 stimulus array of abstract geometric figures (Figure 3). There are three learning trials of 10 s. The array is removed and the patient is required to draw the array from memory, with the correct shapes in the correct position. The psychometric properties of the BVMT-R T1-3 are good.⁴⁵ Validity of the BVMT-R T1-3 has been indicated by significant association with brain MR total lesion area,⁴⁴ T1 lesion and FLAIR lesion volume, BPF and third ventricular width³² and right

superior frontal atrophy⁴⁴ and correlation with some DGM nuclei,³⁷ including thalamic fraction.³²

Implementation

For those health professionals with little experience of cognitive assessment, prior review of instructions and practice is recommended. Testing should take place in a quiet room, with just the patient and the assessor present. The purpose of BICAMS should be explained to the patient and if appropriate, some background information explaining cognitive difficulties in MS should have been made available to the patient in advance (e.g. www.stayingsmart.org.uk). It is recommended that BICAMS should not be used within 1 month of recovery from relapse (or if used, the data should not be interpreted as indicating long-term decline),⁴⁶ or within 1 month of steroid therapy, which has a proven reversible detrimental effect on memory function.⁴⁷ The recommended order of administration is first the SDMT, then if time allows the CVLT-II T1-5 and BVMT-R T1-3. In most clinical situations, yearly or bi-annual BICAMS evaluations will be appropriate.

Confounders and limitations

BICAMS is not intended to replace a full neuropsychological assessment, which provides important additional insights to the patient, family, and clinician. These more detailed evaluations are necessary for in depth rehabilitation and vocational counselling and disability determination.

Neuropsychological test performance, including measures such as the SDMT, CVLT-II, and BVMT-R, is influenced by MS physical symptoms, demographic factors, the presence of concurrent neurological disorders other than MS, some concurrent medications, and to a modest degree depression.

Physical symptoms of MS. Whilst the BICAMS component scales have been selected to minimise the impact of physical impairments on cognitive test performance,^{10,13} the assessor should remain aware of confounders from MS symptoms. For example, dysarthria reduces performance on tests requiring a spoken response, especially if timed.⁴⁸ Even mild MS visual impairments can also affect cognitive tests with visual stimuli.⁴⁹ The experienced clinician can infer how a patient's physical difficulties prejudice their test scores. Aside from the sensory and motor interface with the test situation, there are a number of physical symptoms of MS that can interfere with cognitive test performance, notably pain.¹⁰

Demographic factors. Demographic factors (age, education, and gender) affect cognitive performance. Many tests have normative data taking account of these variables.^{50,51} It is also well established that pre-morbid optimal level will affect how far current deterioration is detectable (cognitive

reserve).⁷ Some countries have reading scales that estimate pre-morbid level.¹⁰ If testing materials are not available in the patient's native language, particularly with respect to verbal learning and memory, published normative data cannot be used with any precision to evaluate the patient's performance. The limited value of BICAMS for patients who are not native speakers is as a baseline against which to measure future change.

Concurrent neurological/medical disorders. If an MS patient has cognitive dysfunction, consideration must be given to whether other co-morbid neurological or medical conditions exist. In the context of learning disability, most mainstream intellectual assessments are inappropriate. It is helpful to ask whether or not a diagnosis of learning difficulty or attention deficit disorder was present prior to the MS diagnosis, or their characteristic features, since these conditions may have been present without formal diagnosis. Questions regarding difficulties in school performance or with reading can yield helpful information. The medical history should include questions regarding past head trauma, cerebrovascular disease, and other medical conditions such as sleep apnoea.

Concurrent medications. Certain medications commonly used in MS can adversely affect cognitive functioning.⁵² Benzodiazepines can interfere with vigilance and memory.⁵³ For many patients high doses of anti-spasticity agents such as baclofen are associated with cognitive impairments.⁵⁴ Anticonvulsants are also known to reduce cognitive function.⁵⁵ Antidepressant medication can cause cognitive inefficiency to varying degrees.⁵² Cannabis, whether prescribed or self-medicated, can influence cognition.⁵⁶ It is also important to be alert to other non-prescribed medication. Recent changes in cognition should be considered in the context of any concurrent medication changes.

Depression. Depression is highly prevalent in MS and may have mild effects on cognitive functioning, possibly mediated by coping styles.⁵⁷ It is likely that severe depression could interfere with either willingness to undergo testing or ability to concentrate. An important aspect of depression's influence on the clinical management of cognition, is that depression affects self-report of cognitive problems. Patients' self-report of cognitive impairment does not reliably correlate with their performance at objective cognitive testing; in contrast, the relative's report of the patient's cognitive status does correlate with the patient's performance at objective cognitive testing.⁵⁸ Treatment of depression (and fatigue) improves patients' self report of cognitive function, but not their objective cognitive test performance.⁸

Fatigue. Over 80% of MS patients experience fatigue and also have the impression that this symptom interferes with

their cognitive functions.⁵⁹ This association has not been consistently confirmed in studies of objective cognitive test performance. However, it is known that heat, infections, pain and depression can increase fatigue and these contributory factors should be managed to ensure optimum cognitive performance. When feasible, patients should be allowed to rest after arriving, before their cognitive assessment, to minimise the effects of fatigue.⁶⁰ Those undergoing repeated testing should if possible be evaluated at the same time of day as the original assessment, to avoid variance from time of day fatigue effects.

Future work and development of BICAMS

An international validation protocol for BICAMS is under development. Several national validation and standardisation projects are under way. It is envisaged that over time, many nations will be able to utilise BICAMS as part of routine clinical MS practice, referring to appropriate national norms. International MS natural history studies and treatment trials with cognition outcomes will be assisted by an internationally standardised battery. In order to support this process and facilitate access to materials and norms, the BICAMS committee is working to publish BICAMS updates in scientific and professional journals and meetings. The BICAMS website (www.BICAMS.net) will be a focus for this process, with a commitment to open access whenever possible.

Summary

An expert consensus committee of neurologists and neuropsychologists, with extensive research and clinical experience of MS cognition, have recommended a Brief International Assessment of Cognition for MS (BICAMS).¹⁶ The battery takes 15 min to complete, requires no specialist equipment and no specialist expertise in cognitive assessment. BICAMS comprises:

- The Symbol Digit Modalities Test
- The California Verbal Learning Test –II, first five recall trials
- The Brief Visuospatial Memory Test –Revised, first three recall trials.

Acknowledgement

This group of authors first came together in a Bayer sponsored meeting, which inspired the foundation of the (independent) BICAMS committee. We acknowledge Bayer's scientific contribution in the area of cognition.

Funding

The BICAMS committee meetings are sponsored by Bayer.

Conflict of interest statement

Professor Langdon has received funding for travel to scientific meetings from Bayer Healthcare; serves on a Steering Committee for Bayer Healthcare; has served/serves as a consultant to Merck-Serono, Bayer Healthcare; served on speaker bureau for Bayer Healthcare, Roche, Serono Symposia, TEVA Germany; receives research contract funding from Bayer Healthcare; receives educational grants from Bayer Healthcare.

Professor Amato received personal compensation from Merck Serono, Biogen Dompè, Sanofi Aventis, Bayer Schering for serving on scientific advisory board and for speaking. Professor Amato received financial support for research activities from Merck Serono, Sanofi Aventis, Biogen Dompè, Bayer Schering.

Dr Boringa has consulted for Bayer Healthcare served on speaker bureau for Exencia Pharma Academy.

Dr Brochet serves on scientific advisory boards for Bayer Schering Pharma, Novartis, and Merck Serono; has received funding for travel and speaker honoraria from Bayer Schering Pharma, Merck Serono, Biogen Idec, AB Sciences, and Teva Pharmaceutical Industries Ltd./Sanofi-Aventis; and serves as LEN editor for SEP et Neurosciences.

Dr Foley has received honoraria for speaking at scientific and patient-education meetings, serving on scientific advisory boards and consulting activities from Bayer–Schering, Biogen, and Teva Neuroscience.

Dr Fredrikson has received honoraria for lectures, educational activities and consultancy from Bayer, Biogen Idec and Sanofi–Aventis during the past year.

Dr Hämäläinen received personal compensation from Bayer Healthcare and Novartis for serving on scientific advisory boards; consulting for Sanofi–Aventis; served on speaker bureau for Bayer Healthcare and Sanofi–Aventis.

Professor Hartung received honoraria with approval by the Rector of Heinrich-Heine-University from Bayer Healthcare GmbH, Octapharma GmbH, Novartis, Teva Sanofi Aventis, Biogen Idec GmbH and Merck Serono GmbH for consulting and speaking at scientific symposia.

Dr Krupp has served on speaker bureaux, scientific advisory boards and/or been a consultant for Teva Neurosciences, BiogenIdec, EMD Serono, Multiple Sclerosis Association of America, Betaseron/Bayer Healthcare Pharmaceuticals, Pfizer, Sanofi–Aventis, Axon Advisors; she has received royalties from Genzyme, ER Squibb & Sons, NMSS, Novartis, MedImmune, Abbott Laboratories, Johnson&Johnson, Roche, Health Professions Conferencing Corp.

Dr Penner has received honoraria for speaking at scientific meetings, serving at scientific advisory boards and consulting activities from Bayer–Schering, Biogen, Merck Serono, Roche, Novartis.

Dr Reder has recently submitted two articles to *Neurology* and his disclosures remain the same.

Professor Benedict has acted as a consultant or scientific advisory board member for Bayer, Biogen Idec, Merck Serono, EMD Serono, Pfizer, Novartis; royalties from Psychological Assessment Resources, Inc; financial support for research activities from Shire Pharmaceuticals, Biogen Idec.

References

1. Langdon DW. Cognition in multiple sclerosis. *Curr Opin Neurol* 2011; 24: 244–249.

2. Amato MP, Portaccio E, Goretti B, et al. Relevance of cognitive deterioration in early relapsing–remitting MS: a 3-year follow-up study. *Mult Scler* 2010; 16: 1474–1482.
3. Amato MP, Portaccio E, Stromillo ML, et al. Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. *Neurology* 2008; 71: 632–638.
4. Filippi M, Rocca MA, Benedict RH, et al. The contribution of MRI in assessing cognitive impairment in multiple sclerosis. *Neurology* 2010; 75: 2121–2128.
5. Langdon D. Cognitive impairment in multiple sclerosis – recent advances and future prospects. *Eur Neurol Rev* 2010; 5: 69–72.
6. Strober L, Englert J, Munschauer F, et al. Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS. *Mult Scler* 2009; 15: 1077–1084.
7. Sumowski JF, Wylie GR, Chiaravalloti N and DeLuca J. Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis. *Neurology* 2010; 74: 1942–1945.
8. Kinsinger SW, Lattie E and Mohr DC. Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis. *Neuropsychology* 2010; 24: 573–580.
9. Sherman TE, Rapport LJ and Ryan KA. Awareness of deficit in multiple sclerosis. *J Clin Exp Neuropsychol* 2008; 30: 301–311.
10. Benedict RH, Fischer JS, Archibald CJ, et al. Minimal neuropsychological assessment of MS patients: a consensus approach. *The Clinical Neuropsychologist* 2002; 16: 381–397.
11. Sicotte NL. Neuroimaging in multiple sclerosis: neurotherapeutic implications. *Neurotherapeutics* 2011; 8: 54–62.
12. Cheng EM, Crandall CJ, Bever CT, et al. Quality indicators for multiple sclerosis. *Mult Scler* 2010; 16: 970–980.
13. Rao SM, the Cognitive Function Study Group of the National Multiple Sclerosis Society. *A Manual for the Brief Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis*. Milwaukee, WI: Medical College of Wisconsin; 1990.
14. Marrie RA, Goldman M. Validity of performance scales for disability assessment in multiple sclerosis. *Mult Scler* 2007; 13: 1176–1182.
15. Aupperle RL, Beatty WW, Shelton Fde N and Gontkovsky ST. Three screening batteries to detect cognitive impairment in multiple sclerosis. *Mult Scler* 2002; 8: 382–389.
16. Langdon D, Amato M, Boringa J, et al. The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): first consensus steps towards a brief universal cognitive assessment for MS. *Neurology* 2011; 76: A479.
17. Christodoulou C, MacAllister WS, McLinskey NA and Krupp LB. Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option? *CNS Drugs* 2008; 22: 87–97.
18. Prakash RS, Snook EM, Lewis JM, Motl RW and Kramer AF. Cognitive impairments in relapsing–remitting multiple sclerosis: a meta-analysis. *Mult Scler* 2008; 14: 1250–1261.
19. Smith A. *Symbol Digit Modalities Test (SDMT) Manual* (revised). Los Angeles: Western Psychological Services; 1982.
20. Drake AS, Weinstock-Guttman B, Morrow SA, Hojnacki D, Munschauer FE and Benedict RH. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. *Mult Scler* 2010; 16: 228–237.
21. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. *Ann Neurol* 2000; 48: 885–92.
22. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. *Lancet Neurol* 2009; 8: 987–997.
23. Benedict RH, Cookfair D, Gavett R, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). *J Int Neuropsychol Soc* 2006; 12: 549–558.
24. Parmenter BA, Weinstock-Guttman B, Garg N, Munschauer F and Benedict RH. Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test. *Mult Scler* 2007; 13: 52–57.
25. Holmén C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. *Mult Scler* 2011; 17: 708–719.
26. Deloire MS, Bonnet MC, Salort E, et al. How to detect cognitive dysfunction at early stages of multiple sclerosis? *Mult Scler* 2006; 12: 445–452.
27. Portaccio E, Goretti B, Zipoli V, et al. Reliability, practice effects, and change indices for Rao’s Brief Repeatable Battery. *Mult Scler* 2010; 16: 611–617.
28. Camp SJ, Stevenson VL, Thompson AJ, et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. *Brain* 1999; 122: 1341–1348.
29. Benedict RH, Duquin JA, Jurgensen S, et al. Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. *Mult Scler* 2008; 14: 940–946.
30. Morrow SA, Drake A, Zivadinov R, Munschauer F, Weinstock-Guttman B and Benedict RH. Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. *The Clinical Neuropsychologist* 2010; 24: 1131–1145.
31. Bomboi G, Ikonomidou VN, Pellegrini S, et al. Quality and quantity of diffuse and focal white matter disease and cognitive disability of patients with multiple sclerosis. *J Neuroimag* 2011 Apr; 21(2): e57–63. (Epub 2011 April).
32. Houtchens MK, Benedict RH, Kiliyany R, et al. Thalamic atrophy and cognition in multiple sclerosis. *Neurology* 2007; 18: 1213–1223.
33. Brochet B, Deloire MS, Bonnet M, et al. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study. *Mult Scler* 2008; 14: 1242–1249.
34. Mike A, Glanz BI, Hildenbrand P, et al. Identification and clinical impact of multiple sclerosis cortical lesions as assessed by routine 3T MR imaging. *AJNR Am J Neuroradiol* 2011; 32: 515–521.
35. Stankiewicz JM, Glanz BI, Healy BC, et al. Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. *J Neuroimag* 2011 Apr; 21(2): e50–6. (Epub 2011 April).

36. Camp SJ, Stevenson VL, Thompson AJ, et al. A longitudinal study of cognition in primary progressive multiple sclerosis. *Brain* 2005; 128: 2891–2898.
37. Benedict RH, Ramasamy D, Munschauer F, Weinstock-Guttman B and Zivadinov R. Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. *J Neurol, Neurosurg Psychiat* 2009; 80: 201–206.
38. Warlop NP, Achten E, Fieremans E, Debruyne J, Vingerhoets G. Transverse diffusivity of cerebral parenchyma predicts visual tracking performance in relapsing–remitting multiple sclerosis. *Brain and Cognition* 2009; 71: 410–415.
39. Einarsson U, Gottberg K, von Koch L, et al. Cognitive and motor function in people with multiple sclerosis in Stockholm County. *Mult Scler* 2006; 12: 340–353.
40. Delis DC, Kramer JH, Kaplan E, Ober BA. *California Verbal Learning Test*, second edition (CVLT-II). San Antonio, TX: Psychological Corporation; 2000.
41. Stegan S, Stepanov I, Cookfair D, et al. Validity of the California Verbal Learning Test-II in multiple sclerosis. *The Clinical Neuropsychologist* 2010; 24: 189–202.
42. Fink F, Eling P, Rischkau E, et al. The association between California Verbal Learning Test performance and fibre impairment in multiple sclerosis: evidence from diffusion tensor imaging. *Mult Scler* 2010; 16: 332–341.
43. Sartori E and Edan G. Assessment of cognitive dysfunction in multiple sclerosis. *J Neurol Sci* 2006; 245: 169–175.
44. Benedict RH, Bakshi R, Simon JH, Priore R, Miller C and Munschauer F. Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis. *J Neuropsych Clin Neurosci* 2002; 14: 44–51.
45. Benedict RHB. *The Brief Visuospatial Memory Test Revised (BVRT-R)*. Lutz, FL: Psychosocial Assessment Resources Inc; 1997.
46. Rozewicz, L, Langdon DW, Davie CA, Ron MA and Thompson AJ. Reversible focal cognitive impairment in multiple sclerosis. *Cognitive Neuropsychiatry* 1996; 1: 17–25.
47. Brunner R, Schaefer D, Hess K, Parzer P, Resch F and Schwab S. Effect of high-dose cortisol on memory functions. *Ann NY Acad Sci* 2006; 1071: 434–437.
48. Smith MM and Arnett PA. Dysarthria predicts poorer performance on cognitive tasks requiring a speeded oral response in an MS population. *J Clin Exp Neuropsychol* 2007; 29: 804–812.
49. Bruce JM, Bruce AS and Arnett PA. Mild visual acuity disturbances are associated with performance on tests of complex visual attention in MS. *J Int Neuropsychol Soc* 2007; 13: 544–548.
50. Boringa JB, Lazeron RH, Reuling IE, et al. The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice. *Mult Scler* 2001; 7: 263–267.
51. Amato MP, Portaccio E, Goretti B, et al. The Rao's Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. *Mult Scler* 2006; 12: 787–793.
52. Oken BS, Flegal K, Zajdel D, et al. Cognition and fatigue in multiple sclerosis: Potential effects of medications with central nervous system activity. *J Rehab Res Dev* 2006; 43: 83–90.
53. Hindmarch I. Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder. *Int J Clin Prac* 2009; 63: 1085–1094.
54. Dario A, Pisani R, Sangiorgi S, Pessina F and Tomei G. Relationship between intrathecal baclofen and the central nervous system. *Acta Neurochir* 2007; 97(Suppl.): 461–464.
55. Stephen LJ and Brodie MJ. Pharmacotherapy of epilepsy: newly approved and developmental agents. *CNS Drugs* 2011; 25: 89–107.
56. Ghaffar O and Feinstein A. Multiple sclerosis and cannabis: a cognitive and psychiatric study. *Neurology* 2008; 71: 164–169.
57. Rabinowitz AR and Arnett PA. A longitudinal analysis of cognitive dysfunction, coping, and depression in multiple sclerosis. *Neuropsychology* 2009; 23: 581–591.
58. Benedict RH, Cox D, Thompson LL, Foley F, Weinstock-Guttman B and Munschauer F. Reliable screening for neuropsychological impairment in multiple sclerosis. *Mult Scler* 2004; 10: 675–678.
59. Krupp LB, Serafin DJ and Christodoulou C. Multiple sclerosis-associated fatigue. *Expert Rev Neurother* 2010; 10: 1437–1447.
60. Ebers GC, Reder AT, Traboulsee A, et al. Long-term follow-up of the original interferon-beta 1b trial in multiple sclerosis: design and lessons from a 16-year observational study. *Clin Therap* 2009; 31: 1724–1736.